Results 251 to 260 of about 530,055 (311)

Dual‐Physical‐Field Nanocatalysis: Injectable Hydrogel Enables Piezo‐Photothermal Synergy for Breast Cancer Therapy

Advanced Science, EarlyView.
ABSTRACT Piezocatalytic therapy (PCT) harnesses mechanical energy to generate tumor‐lethal reactive oxygen species (ROS), but its efficacy is limited by rapid electron‐hole recombination and poor intratumoral retention. To overcome these limitations, we engineered heterostructured BiOCl@CuO nanosheets embedded in an injectable, conductive ...
Can Tian, Shihan Xiao, Xuan Chen, Danni Zhang, Zizhen Liu, Jing Wang, Ning Xie, Wei Li   +7 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Cars2‐Mediated Cysteine Catabolism Drives Brown Fat Development and Thermogenesis Through Persulfidating EBF2

Advanced Science, EarlyView.
We demonstrate that Cars2, a cysteine catabolic enzyme in mouse iBAT, is critical for cold tolerance and brown adipocyte differentiation. Through its CPERS activity, Cars2 produces CysSSH/H2S to induce EBF2 persulfidation, promoting its interaction with PPARγ and BRG1 to enhance thermogenic gene expression.
Xin Peng, Hongyong Song, Yin Long, Kaimin Wu, Yinkun Fu, Wenkai Zhou, Wenyan Li, Zhe Shi, Xu‐Yun Zhao   +8 more
wiley   +1 more source

Detachment‐Induced FAK‐STAT3‐NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation

Advanced Science, EarlyView.
The FAK‐STAT3‐NNMT axis drives anoikis resistance in circulating tumor cells by reprogramming fatty acid oxidation. Targeting this metabolic vulnerability suppresses metastasis, untangling a key mechanism of breast cancer progression and revealing NNMT as a promising therapeutic target.
Qingchao Tong, Yilei Ma, Yuzhen Gao, Lin Zhou, Luping Lou, Qiang Fang, Sining Fang, Ru Zhao, Jin Zeng, Jun Yang, Guoli Li, Xinyou Xie, Yanzhong Wang, Jun Zhang   +13 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Insulin-Like Growth Factor -I Deficiency

Hormone Research in Paediatrics, 2001
The insulin-like growth factor (IGF) system composed of two ligands, their receptors and regulatory proteins (acid-labile subunit and IGF-binding proteins) plays a central role in the regulation of growth and development in mammals. In addition to its key role in the stimulation of cellular proliferation and growth, IGF-I has important effects on ...
C, Camacho-Hübner, M, Savage
openaire   +2 more sources

Insulin-Like Growth Factor I

Drugs & Aging, 2000
According to the somatomedin model, growth hormone (GH)-dependent hepatic synthesis is responsible for maintaining circulating insulin-like growth factor (IGF)-I levels. On the other hand, the local autocrine/paracrine IGF-I expression in peripheral tissue is generally GH-independent and reflects the effects of various and tissue-specific trophic ...
ARVAT, Emanuela, BROGLIO, Fabio, GHIGO, Ezio   +2 more
openaire   +3 more sources

Colocalization of insulin-like growth factor-binding protein with insulin-like growth factor I

American Journal of Physiology-Renal Physiology, 1991
We report the localization of insulin-like growth factor I (IGF-I) and a 25-kDa form of insulin-like growth factor-binding protein (IGF-BP-1) in adult rat kidney. The antigens were localized using a rabbit anti-human IGF-I antibody, and a rabbit anti-human IGF-BP-1 antibody raised against human 25-kDa IGF-BP-1 purified from amniotic fluid ...
S, Kobayashi, D R, Clemmons, M A, Venkatachalam   +2 more
openaire   +2 more sources

Insulin-like growth factor-I: Clinical studies

Drugs of Today, 1998
Insulin-like growth factor-I (IGF-I) has endocrine, autocrine and paracrine properties. Receptors for IGF-I are present on virtually all cell types but are located mainly on cells of mesenchymal origin, such as fibroblasts, chondrocytes and osteoblasts. Growth hormone (GH)-dependent and GH-independent actions of IGF-I have been implicated in normal and
P E, Vos, H P, Koppeschaar, W R, de Vries, J H, Wokke   +3 more
openaire   +2 more sources

Insulin‐like growth factor I actions on steroidogenesis

Acta Paediatrica, 1994
The best evidence that insulin‐like growth factor I (IGF‐I) contributes to normal steroidogenesis comes from patients with growth hormone (GH) insensitivity syndrome due to deletion of the GH receptor gene. These patients have severe GH resistance and severe IGF‐I insufficiency, and present with markedly delayed puberty without gonadotrophin ...
Chatelain, P.G., Avallet, O., Nicolino, M., Lejeune, Hervé, Clark, A., Chuzel, F., Penhoat, Armelle, Saez, J.M.   +7 more
openaire   +3 more sources

Insulin-like Growth Factor-I in Growth and Metabolism

Journal of Pediatric Endocrinology and Metabolism, 2010
Deficiency of insulin-like growth factor-I (IGF-I) results in growth failure. A variety of molecular defects have been found to underlie severe primary IGF-I deficiency (IGFD), in which serum IGF-I concentrations are substantially decreased and fail to respond to GH therapy.
Backeljauw, P, Bang, P, Dunger, D B, Juul, A, Le Bouc, Y, Rosenfeld, R   +5 more
openaire   +3 more sources